Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Biogen Idec will acquire Syntonix Pharmaceuticals, a private biopharmaceutical firm with several preclinical programs in hemophilia. Syntonix also has drug delivery technologies that harness the body's natural pathways to protect antibodies against premature destruction and that transport antibodies across cell barriers. Biogen Idec will pay Syntonix' owners $40 million up front and could make additional payments of up to $80 million upon achievement of development milestones.
This article has been sent to the following recipient: